Masimo Corporation $MASI Shares Sold by TD Asset Management Inc

TD Asset Management Inc trimmed its stake in Masimo Corporation (NASDAQ:MASI) by 35.5% in the third quarter, HoldingsChannel.com reports. The fund owned 107,858 shares of the medical equipment provider’s stock after selling 59,318 shares during the quarter. TD Asset Management Inc’s holdings in Masimo were worth $15,914,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Clearstead Advisors LLC raised its position in shares of Masimo by 18.4% in the third quarter. Clearstead Advisors LLC now owns 470 shares of the medical equipment provider’s stock valued at $69,000 after buying an additional 73 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Masimo by 133.5% during the third quarter. Citigroup Inc. now owns 116,672 shares of the medical equipment provider’s stock worth $17,215,000 after purchasing an additional 66,710 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new stake in shares of Masimo in the third quarter valued at $12,491,000. NEOS Investment Management LLC increased its stake in Masimo by 13.5% in the third quarter. NEOS Investment Management LLC now owns 4,482 shares of the medical equipment provider’s stock valued at $661,000 after purchasing an additional 533 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Masimo by 3.7% during the third quarter. Vanguard Group Inc. now owns 4,810,011 shares of the medical equipment provider’s stock worth $709,717,000 after buying an additional 171,876 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MASI has been the subject of several research analyst reports. BTIG Research lowered shares of Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Monday, December 1st. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price on the stock. in a research report on Tuesday, February 17th. Wolfe Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Finally, Bank of America initiated coverage on Masimo in a research report on Monday, November 17th. They issued a “neutral” rating and a $162.00 target price for the company. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $181.17.

Masimo Price Performance

NASDAQ MASI opened at $175.35 on Monday. Masimo Corporation has a 12 month low of $125.94 and a 12 month high of $194.88. The firm has a market capitalization of $9.42 billion, a PE ratio of -16.64, a P/E/G ratio of 1.78 and a beta of 1.21. The company’s 50 day simple moving average is $143.09 and its 200 day simple moving average is $143.94. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.